NEW YORK--(BUSINESS WIRE)--IntelliCell BioSciences, Inc. (OTCQB: SVFC.PK) ("IntelliCell" or the "Company"), James R. Andrews, M.D. and Joshua Hackel, M.D. of the Andrews Institute of Orthopedic and Sports Medicine in Gulf Breeze, FL have joined IntelliCell BioSciences Medical Advisory Board. Dr. Steven Victor, CEO, of IntelliCell BioSciences said, "We are extremely excited to welcome Dr. Andrews and Dr. Hackel as scientific advisors to our company. In addition, we are exploring the establishment of an IntelliCell Center of Excellence at the Andrews Institute to conduct clinical research in the use of Stromal Vascular Fracture SVF cells manufactured through our propriety non-enzymatic process."
Other doctors associated with our company have already successfully treated several professional athletes with outstanding results. Dr. Andrews and his team's scientific exploration of our technology may lead to professional athletes' increased interest in IntelliCell SVF cell therapy. We believe that the sports injury market will perhaps be among the first markets to rapidly adapt this therapy.
There are approximately 17,000 professional athletes and 50,000 NCAA Level 1 athletes in the United States. We estimate that the market for this therapy to be in excess of $1.5 billion. Success in this market will launch SVF cell therapy into the much larger general population.
Dr. Andrews said, "We at the Andrews Institute hope the amount of SVF cells IntelliCell's proprietary process captures will enable physicians to treat sports medicine injuries more effectively and enhance "mother nature's" healing properties. We are looking forward to conducting further research in this exciting area of regenerative medicine including level I and level II clinical research trails."
Presently, Dr. Andrews is internationally known throughout the world for his scientific and clinical research contributions in knee, shoulder, and elbow injuries as well as his expertise as an orthopedic surgeon. He is a past president of the American Orthopedic Society of Sports Medicine and a member of the American Academy of Orthopedic Surgeons. He is the Senior Orthopedic Consultant for the Washington Redskins professional football team, and the Medical Director for the Tampa Bay Rays professional baseball team. Dr Andrews is a past member of the Sports Medicine Committee of the US Olympic Committee and he currently serves on the Medical and Safety Advisory Committee of USA Baseball.
About IntelliCell BioSciences, Inc.
IntelliCell is a pioneering regenerative medicine company focused on the expanding regenerative medical markets using stromal vascular fraction derived from adult adipose tissue. IntelliCell intends to initially focus on selling laboratory suites and licensing its technology to doctors for use in their offices for their patients. The company is also setting up Centers of Excellence where doctors can treat their patients. In addition, IntelliCell BioSciences in exploring storing the stromal vascular fraction in cryostorage for future uses. The company is also starting FDA IND clinical trials at major medical centers for clinical indication approval. IntelliCell intends to pursue expansion to secondary markets and beyond the U.S. through a combination of company-owned and licensed clinical facilities. For additional information, visit http://www.intellicellbiosciences.com or call 212-249-3050.